The old ADC story was clean and satisfying: find the cancer cell, dock, enter, release payload, cue dramatic explosion. Tumors, naturally, refused to cooperate. Breast cancers are patchy. One region waves the HER2 flag, another barely mutters it. Some cells internalize drugs nicely, others act like they never signed for the package. And the surrounding microenvironment - immune cells, fibroblasts, blood vessels, extracellular matrix - can behave like a maze full of locked doors and bad lighting [1,3,6].
That is why this review matters. Lu et al. argue that ADCs should no longer be viewed as simple delivery trucks. They can also reshape the terrain around the tumor. When ADCs kill cancer cells, that death may be immunogenic, meaning it can release distress signals and tumor bits that wake up the immune system. In other words, the blast does not just hit the target - it can also alert the neighborhood watch, which in cancer has been napping on the job [1].
The tumor's defense budget is annoyingly high
The tumor microenvironment is one of cancer's better scams. It can block drug penetration with dense stroma, suppress immune attacks with inhibitory signals, and help resistant clones survive like backup players suddenly turning into playoff villains [1,6]. If your tumor were running a fortress, the microenvironment would handle walls, smoke machines, and a deeply corrupt security team.
That helps explain why newer ADC design is getting more tactical. Researchers are tweaking all three major parts of the weapon system: the antibody target, the linker, and the payload. Targets have expanded beyond HER2 to include TROP-2 and HER3, opening options for people whose cancers used to fall into the medical category of "well, this is awkward" [1,2,3]. Linkers are being engineered to release drugs more selectively in tumor conditions. Payloads are being optimized not just for raw killing power, but for bystander effects and possible immune activation [1,3].
And then there is the combination strategy. If ADCs can injure the tumor and stir immune activity, maybe checkpoint inhibitors can exploit that opening. That is the chess match here: one move cracks the wall, the next move sends in the cavalry. Reviewers covering breast cancer and broader solid tumors both point to combination therapy as one of the field's most active next fronts, even if the final playbook is still being written [4,6].
Why this is more than biotech gadget worship
The real-world promise is not just "better drug, more science, nice graphs." It is more patients getting useful treatment in breast cancer subtypes that historically had fewer targeted options, especially metastatic triple-negative disease and HER2-low disease [1,4,5]. Trastuzumab deruxtecan already showed that "HER2-low" was not a meaningless middle child category after all [5]. Sacituzumab govitecan pushed further in heavily pretreated HR-positive, HER2-negative metastatic disease [4]. That is a big deal because metastatic breast cancer does not care how elegant your pathway diagram looks at 2 a.m.
If the microenvironment-reprogramming angle holds up, the next generation of ADCs could do more than hit visible tumor cells. They might help make cold, resistant tumors more vulnerable to immune attack and improve how far treatment penetrates into heterogeneous disease. Not a magic bullet, because oncology has enough magic-bullet history to make everyone twitchy, but potentially a smarter campaign.
The catch, of course, is that cancer also evolves. Resistance still shows up. Toxicities still matter. Sequencing one ADC after another may not work cleanly if tumors learn the payload's tricks or alter antigen expression [3,6]. So the field is moving from "can we build a guided missile?" to "can we run an adaptive military campaign without accidentally blowing up the supply line?" Much harder question. Much more interesting one.
References
-
Lu N, Yan B, Li YQ, Wan JL. Evolving antibody-drug conjugates in breast cancer from precision delivery to tumor microenvironment reprogramming. Journal of Hematology & Oncology. 2026. DOI: 10.1186/s13045-026-01799-2
-
Davis AA, Hesse J, et al. Novel treatment approaches utilizing antibody-drug conjugates in breast cancer. npj Breast Cancer. 2025;11:42. DOI: 10.1038/s41523-025-00743-w
-
Guidi L, Boldrini L, Trapani D, Curigliano G. Antibody-drug conjugates in metastatic breast cancer: sequencing, combinations and resistances. Current Opinion in Oncology. 2024;36(6):487-494. DOI: 10.1097/CCO.0000000000001087
-
Rugo HS, Bardia A, Marmé F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402(10411):1423-1433. DOI: 10.1016/S0140-6736(23)01245-X
-
Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. New England Journal of Medicine. 2022;387. DOI: 10.1056/NEJMoa2203690. PMCID: PMC10561652
-
Li C, Liu Y, Ji Z, et al. The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors. Journal of Hematology & Oncology. 2024;17:1. DOI: 10.1186/s13045-023-01509-2. PMCID: PMC10768262
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.